Resource utilization included surgical procedures, implants, spectacles, visits to ophthalmologists and eye-centers, transportation, and time lost by patients. Discount rates and sensitivity analyses were performed. Two perspectives were considered: Sickness Fund (SF) and Societal. RESULTS: Spectacle-free rates were >80% for ReSTOR® and 40% for MFIOLs. Mean lifetime numbers of spectacles purchased were 4.2 with ReSTOR®, 12.7 with MFIOLs, and 21.3 without PS. Early PS avoided 0.80 late cataract surgeries per subjects. Surgical procedure costs were €3292 for ReSTOR® and €2292 for other MFIOLs, respectively. From the societal perspective, total undiscounted costs for ReSTOR® were €5268, €7170 for other MFIOLs, and €8492 without PS. With a 3% discount rate, these costs were €4569, €5071 and €4244, respectively. From the SF perspective, total undiscounted costs were €146 with ReSTOR®, €437 with MFIOLs, and €1.688 without PS. With a 3% discount rate, these costs were €76, €227 and €747, respectively. CONCLUSION: PS should decrease the undiscounted costs of vision care from both perspectives. For SF it is highly beneficial while PS remains unlisted for reimbursement. For Society, the discounted incremental cost of avoiding spectacles at age 45 was less than €9/year. ReSTOR® improves patients' lifestyle and is a cost-effective alternative versus spectacles in presbyopic patients.
PEY12 MODELING THE COSTS AND CONSEQUENCES OF RESTOR®, A MULTIFOCAL INTRAOCULAR LENS (IOL), AFTER CATARACT SURGERY IN FRANCE
Alcon France, Rueil-Malmaison, France, 2 Cemka-Eval, Bourd-la-Reine, France, 3 Cemka-Eval, Bourg-la-Reine, France OBJECTIVE: To compare the lifetime costs and consequences of liberating patients from spectacles, after cataract surgery, by implanting the multifocal IOL "ReSTOR®" versus monofocal IOLs. METHODS: A Markov model was created to follow patient cohorts from cataract surgery until death. Prevalence rates of patients not needing spectacles after cataract surgery were obtained from a clinical trial. Resource utilization included implant surgery, IOLs, spectacles, visits to ophthalmologists and eye centers, transportation, and time lost by patients. Economic perspectives were those of Society and Sick Funds (SF). Mortality rates were introduced into the model. Discount rates were applied. Sensitivity analyses were performed. Patients were followed from age 70 to 100 years. RESULTS: More than 80% of patients implanted with ReSTOR® were spectacle-free compared to about 10% with monofocal IOLs. The mean number of spectacles purchased was 1.7 after ReSTOR® and 7.6 after monofocal IOLs. Surgical costs were €3292 for ReSTOR® and €2292 for monofocal IOLs. From the societal perspective, total undiscounted cost estimates were €4384 with ReSTOR® compared to €5359 with monofocal IOLs. With a 3% discount rate these costs became €4226 and €4654, respectively. From the SF perspective, total undiscounted cost estimates were €2350 with ReSTOR® and €2553 with monofocal IOLs. With a 3% discount these costs became €2334 and €2481, respectively. Costs and intervals between spectacle replacements were the most sensitive parameters. CONCLUSION: From both the societal and SF perspectives, undiscounted savings achieved by liberating patients from spectacles counterbalanced the initially higher cost of ReSTOR®. For Society, the discounted incremental cost of avoiding spectacles after ReSTOR® implants was less than €13/year, and SF saved money. ReSTOR® improves patients' lifestyle and is a cost-effective alternative versus spectacles in patients requiring cataract surgery. The objective of this study was to estimate the societal costs and the quality of life among patients with late stage POAG. METHODS: Charts of late stage POAG patients in France, Germany, the UK and Denmark were reviewed and the patients were interviewed. Costs and utility values of health related quality of life were estimated (based on resource use multiplied with unit costs and on EQ-5D questionnaire). RESULTS: 162 patients were included. Average level of visual acuity was 0.28 and 0.11 of the best and worst eye, respectively. Annual health maintenance costs of late stage glaucoma patients are €830 (SD: €445). This does not include costs of surgery and larger procedures. Purchase costs of devices amount to €2045 per patient. Most importantly, however, are costs of home care, which average €2703 per year. With respect to the health related quality of life the average score is 0.67 and best predictor of QoL is visual acuity of the patients' best eye (negatively correlated, p = 0.005). Best eye visual acuity is also negatively correlated with health care maintenance costs (p = 0.024). With respect to home care costs the correlation is positive but not significant. CON-CLUSIONS: This study shows that late stage glaucoma is associated with considerable health care and-in particular-social care costs (home care). It is an important finding that maintenance health care costs is negatively correlated with visual acuity (and thereby QoL). A lower visual acuity is predictive of lower QoL. Scandinavia) . METHODS: Cost-effectiveness analysis was performed using a Markov decision-analytic health economic model with stable and progressed glaucoma as the health states. Transition probabilities for primary open-angle and exfoliation glaucoma were derived from published medical literature, and information regarding clinical practice patterns was obtained from surveys completed by 45 ophthalmologists dispersed throughout each of the countries. Country-specific unit costs were used for medications, clinic visits, diagnostics, and outpatient services. Quality of life weights for various levels of visual acuity ranged from 0.50 to 0.68, and the effectiveness metric was the quality-adjusted life year (QALY). A 5-year time horizon was adopted, analyses were from a payer perspective, and costs were discounted at 3% per year. RESULTS: Effectiveness (years till progression) was within a narrow range (3.2048 to 3.2613 QALYs) across all products in each country. Latanoprost was 3% less expensive than bimatoprost and travoprost in Norway and Sweden, and the costs of the 3 agents were within 1% of each other in Denmark. Latanoprost dominated (i.e., was more effective and less expensive than) bimatoprost and travoprost in Norway and Sweden. In Denmark, bimatoprost dominated travoprost. Although bimatoprost was slightly less expensive than latanoprost in Denmark (DKK 28,700 vs 29,000, respectively), latanoprost was more effective yielding an incremental cost-effectiveness ratio of DKK 47,871. CONCLUSIONS: In Scandinavia, latanoprost was more cost-effective than other available prostaglandin analogues over a 5-year period. (Scandinavia) , and the UK (UK). METHODS: Cost-effectiveness analysis was performed using a Markov model. The health states were stable and progressed glaucoma. Transition probabilities for primary open-angle and exfoliation glaucoma were derived from the medical literature, and data concerning practice patterns were obtained from surveys completed by 54 ophthalmologists geographically dispersed throughout each of the countries. Country-specific unit costs were assigned for medications, patient visits, diagnostics, and therapeutic procedures. Quality of life weights for various levels of visual acuity ranged from 0.50 to 0.68. A payer perspective with a 5-year time horizon was adopted and costs were discounted at 3% for Scandinavia or 3.5% for the UK per year. RESULTS: Latanoprost was less expensive than timolol, ranging from 5.4% to 6.7% less in Scandinavia and by 2.1% less in the UK. The range of effectiveness (years to progression of glaucoma) between treatment cohorts was narrow, from 0.003 to 0.01, which may have reflected the fact that the design assumed that physicians control most patients' glaucoma over 5 years by adding or changing therapy. Incremental cost-effectiveness ratios for latanoprost versus timolol were DKK 447, 857 in Denmark, NOK 457, 212 in Norway, SEK 1, 251, 126 in Sweden, and GBP 6087 Pfizer, Tadworth, Surrey, UK OBJECTIVES: To estimate the cost-effectiveness of pegaptanib versus best supportive care for age-related macular degeneration (ARMD) in the UK and to evaluate the impact of patient characteristics. METHODS: A 10-year Markov model was constructed composed of 13 health states, 12 visual acuity (VA) states defined by individual Snellen lines and death. Timedependent transition probabilities for the loss and gain of Snellen lines were derived from parametric survival models fitted to patient-level data from the VISION trial. Survival models were fitted with treatment group and baseline Snellen score as covariates, and other models were fitted with the addition of age, gender, and lesion type or lesion size. Mortality rates were adjusted for the age and gender of the model population. Utility weights elicited using a choice-based method were derived from the published literature. Resource use estimates were developed by structured interview of three consultant ophthalmologists. Other model parameters were obtained from the published literature; unit costs were obtained from national sources (cost year 2005). Uncertainty was explored by probabilistic and univariate sensitivity analysis. RESULTS: In the base-case analysis, treatment was targeted to patients with VA of 20/40 to 20/320 and was discontinued if VA fell below 20/320 or by 6 or more lines. The incremental cost per quality adjusted life year gained (IC/QALY) was estimated as £8023 [upper 95% CI: £20, 641] . Age had the greatest impact [age <75: £2033/QALY; age ≥75: £11,657/QALY]. Pre-treatment VA was also important [20/40 to 20/320: £8023/QALY; 20/40 to 20/200: £6664/QALY]. Gender, lesion type, and lesion size had little effect on the IC/QALY [all estimates were between £7000 and £9000/QALY]. CONCLU-SIONS: Pegaptanib treatment is expected to be cost-effective across all groups studied, and marginally more cost-effective in younger patients and those with better pre-treatment VA.
PEY14 BIMATOPROST, LATANOPROST, AND TRAVOPROST FOR THE TREATMENT OF GLAUCOMA: A COST-EFFECTIVENESS ANALYSIS IN SCANDINAVIA USING A DECISION-ANALYTIC HEALTH ECONOMIC MODEL
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